Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec;478(12):2739-2762.
doi: 10.1007/s11010-023-04696-1. Epub 2023 Mar 22.

New insights toward molecular and nanotechnological approaches to antidiabetic agents for Alzheimer's disease

Sweta Priyadarshini Pradhan  1 , Pratap Kumar Sahu  1 , Anindita Behera  2
Affiliations
Review

New insights toward molecular and nanotechnological approaches to antidiabetic agents for Alzheimer's disease

Sweta Priyadarshini Pradhan et al. Mol Cell Biochem. 2023 Dec.

Abstract

Alzheimer's disease (AD) is a chronic neurodegenerative disorder affecting a major class of silver citizens. The disorder shares a mutual relationship on account of its cellular and molecular pathophysiology with type-II diabetes mellitus (DM). Chronic DM increases the risk for AD. Emerging evidence recommended that resistance in insulin production develops cognitive dysfunction, which generally leads to AD. Repurposing of antidiabetic drugs can be effective in preventing and treatment of the neurodegenerative disorder. Limitations of antidiabetic drugs restrict the repurposing of the drugs for other disorders. Therefore, nanotechnological intervention plays a significant role in the treatment of neurological disorders. In this review, we discuss the common cellular and molecular pathophysiologies between AD and type-II DM, the relevance of in vivo models of type II DM in the study of AD, and the repurposing of antidiabetic drugs and the nanodelivery systems of antidiabetic drugs against AD.

Keywords: Alzheimer’s disease; Antidiabetic drugs; Nanodelivery systems; Type II diabetes mellitus.

PubMed Disclaimer

References

    1. Baranowska-Wójcik E, Szwajgier D (2020) Alzheimer’s disease: review of current nanotechnological therapeutic strategies. Expert Rev Neurother 20:271–279. https://doi.org/10.1080/14737175.2020.1719069 - DOI - PubMed
    1. WHO (2020) Dementia fact sheet. World Health Organization, Geneva
    1. Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K et al (2017) Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin 38:1205–1235. https://doi.org/10.1038/aps.2017.28 - DOI - PubMed
    1. DeTure MA, Dickson DW (2019) The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener 14:1–8. https://doi.org/10.1371/journal.pone.0032792 - DOI
    1. Savelieff MG, Nam G, Kang J, Lee HJ, Lee M, Lim MH (2018) Development of multifunctional molecules as potential therapeutic candidates for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis in the last decade. Chem Rev 119:1221–1322. https://doi.org/10.1021/acs.chemrev.8b00138 - DOI - PubMed

MeSH terms

LinkOut - more resources